Brokerages Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) PT at $54.20

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has received an average rating of “Buy” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $54.20.

A number of brokerages have recently commented on TARS. The Goldman Sachs Group lifted their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th. Oppenheimer raised their price objective on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Finally, William Blair raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Franklin Resources Inc. increased its position in shares of Tarsus Pharmaceuticals by 9.3% during the third quarter. Franklin Resources Inc. now owns 12,164 shares of the company’s stock worth $444,000 after buying an additional 1,033 shares during the period. Geode Capital Management LLC lifted its holdings in Tarsus Pharmaceuticals by 8.1% in the third quarter. Geode Capital Management LLC now owns 835,790 shares of the company’s stock valued at $27,494,000 after buying an additional 62,555 shares during the period. Barclays PLC boosted its position in Tarsus Pharmaceuticals by 345.9% during the third quarter. Barclays PLC now owns 98,663 shares of the company’s stock valued at $3,246,000 after acquiring an additional 76,538 shares during the last quarter. Wellington Management Group LLP grew its holdings in Tarsus Pharmaceuticals by 14.2% during the 3rd quarter. Wellington Management Group LLP now owns 145,347 shares of the company’s stock worth $4,780,000 after acquiring an additional 18,019 shares during the period. Finally, Ikarian Capital LLC raised its position in shares of Tarsus Pharmaceuticals by 28.7% in the 3rd quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock worth $33,886,000 after acquiring an additional 230,000 shares in the last quarter. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Up 3.2 %

Shares of TARS opened at $52.45 on Friday. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of -13.77 and a beta of 1.00. Tarsus Pharmaceuticals has a 52 week low of $15.60 and a 52 week high of $52.99. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock has a fifty day moving average of $41.05 and a 200-day moving average of $33.34.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.